Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the licensing agreement, Zambon will commercialize IPX203, an oral formulation of carbidopa/levodopa extended-release capsules designed for the treatment of Parkinson’s disease.
Lead Product(s): Carbidopa,Etilevodopa
Therapeutic Area: Neurology Product Name: IPX203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zambon Group SpA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 27, 2024
Details:
FML® suspension (fluorometholone) is a glucocorticoid receptor agnist. Its generic is approved by USFDA for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe.
Lead Product(s): Fluorometholone
Therapeutic Area: Ophthalmology Product Name: Fluorometholone-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2024
Details:
Under the agreement, Amneal will have exclusive rights to market and distribute ONGENTYS (opicapone), a highly-selective COMT inhibitor, which is approved by USFDA as an add-on treatment to carbidopa/levodopa in patients with Parkinson’s disease experiencing Off episodes.
Lead Product(s): Opicapone
Therapeutic Area: Neurology Product Name: Ongentys
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Bial
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 07, 2023
Details:
Under the agreement, Amneal in-licensed Icosapent ethyl acid soft gel capsules, a product referencing Vascepa and an ethyl ester of eicosapentaenoic acid that is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Lead Product(s): Icosapent Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vascepa-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Amneal Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 01, 2023
Details:
Under the terms of agreement, mAbxience will fully develop the biosimilar, Denosumab (ref Prolia and XGEVA) and manufacture in it's GMP-approved facilities, while Amneal will guide the product through regulatory approval and have exclusive commercialization rights in the US.
Lead Product(s): Denosumab
Therapeutic Area: Musculoskeletal Product Name: MB-09
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Mabxience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 12, 2023
Details:
Calcium gluconate in sodium chloride injection is a small volume parenteral bag indicated for the treatment of acute symptomatic hypocalcemia in pediatric and adult patients.
Lead Product(s): Calcium Gluconate
Therapeutic Area: Nutrition and Weight Loss Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
Sevelamer carbonate film coated tablet is a phosphate binder indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.
Lead Product(s): Sevelamer Hydrochloride
Therapeutic Area: Nephrology Product Name: Renvela-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
Lisdexamfetamine dimesylate capsules, for oral use is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder and Moderate to Severe Binge Eating Disorder (BED) in adults.
Lead Product(s): Lisdexamfetamine Dimesylate
Therapeutic Area: Psychiatry/Psychology Product Name: Vyvanse-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2023
Details:
Albuterol sulfate inhalation powder is first and only breath-actuated, digital SABA inhaler, which is used for prevention of bronchospasm related to exercise-induced or reversible obstructive airway disease.
Lead Product(s): Salbutamol Sulphate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Proair HFA-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2023
Details:
sodium oxybate oral solution indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
Lead Product(s): Sodium Oxybate
Therapeutic Area: Sleep Product Name: Xyrem-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023